Wu Jianfeng, Luan Yingyi, Ke Lu
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510010, Guangdong, China.
The Fourth Medical Center and Medical Innovation Research Division of the Chinese PLA General Hospital, Beijing 100048, China.
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Nov;32(11):1281-1289. doi: 10.3760/cma.j.cn121430-20201123-00719.
This expert consensus uses clinical research evidence to explain the mechanism, monitoring and evaluation of sepsis-induced immunosuppression, and treatment with immune stimulation from two aspects: innate immunity and acquired immunity, aiming to help clinicians better understand sepsis-induced immune depression and its clinical significance. Clinical data suggest that the immune dysfunction is critically involved in the occurrence and development of sepsis. Quantitative detection of monocyte human leukocyte antigen DR and lymphocyte count can be used as important indicators to reflect the innate immune and acquired immune dysfunction in patients with sepsis. Immunomodulation therapy includes medication to improve innate immunity and acquired immunity, and immune stimulation combined with anti-inflammatory response.
本专家共识利用临床研究证据，从固有免疫和获得性免疫两个方面阐释脓毒症诱导免疫抑制的机制、监测与评估以及免疫刺激治疗，旨在帮助临床医生更好地理解脓毒症诱导的免疫抑制及其临床意义。临床资料表明，免疫功能障碍在脓毒症的发生发展中起关键作用。单核细胞人类白细胞抗原DR定量检测及淋巴细胞计数可作为反映脓毒症患者固有免疫和获得性免疫功能障碍的重要指标。免疫调节治疗包括改善固有免疫和获得性免疫的药物治疗，以及免疫刺激与抗炎反应相结合的治疗。
